Literature DB >> 32825957

Chordomas: A review with emphasis on their pathophysiology, pathology, molecular biology, and genetics.

Georgia Karpathiou1, Jean Marc Dumollard2, Maroa Dridi2, Pierre Dal Col2, Fabrice-Guy Barral3, Jean Boutonnat4, Michel Peoc'h2.   

Abstract

Chordomas are uncommon, bone, axial, or (rarely) extra-axial tumors that are malignant and frequently recur but less commonly metastasize. They usually affect adults, with a very small proportion being pediatric tumors. For children, such tumors present a different biology, since they are more common as scull rather than sacral tumors, with aggressive histological features, including a loss of SMARCB1/INI1 and a dismal prognosis. Histologically, chordomas, believed to derive from notochordal tissue, characteristically show physaliphorous cells in a myxoid or chondroid matrix. Dedifferentiated and poorly differentiated forms can be observed. Moreover, a grading scale for chordomas has been proposed. Cytokeratin, EMA, S100, and brachyury are expressed by most chordomas. These are chemo-resistant tumors, for which surgical resection and/or radiotherapy are the treatments of choice. In this review, the histological, immunohistochemical, molecular, and clinical data of chordomas are discussed.
Copyright © 2020 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Bruchyury; Chordoma; Histology; Notochord; Notochordal tumor

Mesh:

Substances:

Year:  2020        PMID: 32825957     DOI: 10.1016/j.prp.2020.153089

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  5 in total

1.  Immune Checkpoint Inhibitors Have Clinical Activity in Patients With Recurrent Chordoma.

Authors:  Andrew J Bishop; Behrang Amini; Heather Lin; Shaan M Raza; Shreyaskumar Patel; David R Grosshans; Amol Ghia; Ahsan Farooqi; B Ashleigh Guadagnolo; Devarati Mitra; Kadir C Akdemir; Alexander J Lazar; Wei-Lien Wang; Christopher Alvarez-Breckenridge; Justin Bird; Laurence D Rhines; Neeta Somaiah; Anthony P Conley
Journal:  J Immunother       Date:  2022-08-04       Impact factor: 4.912

2.  Autophagic Markers in Chordomas: Immunohistochemical Analysis and Comparison with the Immune Microenvironment of Chordoma Tissues.

Authors:  Georgia Karpathiou; Maroa Dridi; Lila Krebs-Drouot; François Vassal; Emmanuel Jouanneau; Timothée Jacquesson; Cédric Barrey; Jean Michel Prades; Jean Marc Dumollard; David Meyronet; Jean Boutonnat; Michel Péoc'h
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

3.  Personalized chordoma organoids for drug discovery studies.

Authors:  Ahmad Al Shihabi; Ardalan Davarifar; Huyen Thi Lam Nguyen; Nasrin Tavanaie; Scott D Nelson; Jane Yanagawa; Noah Federman; Nicholas Bernthal; Francis Hornicek; Alice Soragni
Journal:  Sci Adv       Date:  2022-02-16       Impact factor: 14.136

4.  Pediatric chordoma associated with tuberous sclerosis complex: A rare case report with a thorough analysis of potential therapeutic molecular targets.

Authors:  Kirill Anoshkin; Denis Zosen; Kristina Karandasheva; Maxim Untesco; Ilya Volodin; Ekaterina Alekseeva; Anna Parfenenkova; Eugenia Snegova; Aleksandr Kim; Marina Dorofeeva; Sergei Kutsev; Vladimir Strelnikov
Journal:  Heliyon       Date:  2022-08-19

5.  Chordoma at the skull base, spine, and sacrum: A pictorial essay.

Authors:  Sin Hang Lee; Kai Yan Kwok; Sin Man Wong; Chik Xing Jason Chan; Yu Ting Wong; Man Lung Tsang
Journal:  J Clin Imaging Sci       Date:  2022-08-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.